Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? - Sorbonne Université
Journal Articles Lupus Year : 2023

Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?

Domains

Human health and pathology Immunology Immunotherapy
Fichier principal
Vignette du fichier
Main Document.pdf (178.49 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Paul Breillat  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-04080166

Submitted on : Monday, July 3, 2023-10:02:35 AM

Last modification on : Friday, April 19, 2024-1:20:30 PM

Download

Dates and versions

hal-04080166 , version 1 (03-07-2023)

Identifiers

Cite

Paul Breillat, Alexis Mathian, Flore Rozenberg, Amélie Dutheil, Annick Barbaud, et al.. Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?. Lupus, 2023, 32 (3), pp.453-455. ⟨10.1177/09612033231153536⟩. ⟨hal-04080166⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

SORBONNE-UNIVERSITE SU-MEDECINE
7 View
28 Download

Altmetric

Share

More